KIR3DL1 and neuroblastoma: Recently, killer immunoglobulin-like receptor (KIR) genotypes have been shown to influence clinical outcomes in neuroblastoma patients receiving IL-2 immunotherapy or anti-GD1 antibody treatment8,9.